Aridis Pharmaceuticals, Inc. (ARDS)


+0.03 (+1.64%)
Symbol ARDS
Price $1.86
Beta 1.133
Volume Avg. 0.13M
Market Cap 32.925M
Shares () -
52 Week Range 0.88-4.34
1y Target Est -
DCF Unlevered ARDS DCF ->
DCF Levered ARDS LDCF ->
ROE 137.98% Strong Buy
ROA -75.55% Strong Sell
Operating Margin -
Debt / Equity -216.70% Sell
P/E -
P/B -1.61 Sell


Consensus EPS

Upgrades & Downgrades

Latest ARDS news

Dr. Vu L. Truong
NASDAQ Capital Market

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.